Figure 3.

LBH589 increases the immunogenicity of melanoma. (A) Indicated melanoma cell lines were plated overnight. The following day, cells were treated with 50nM LBH589 or equivalent volume of DMSO for 48 hours. Cells were assessed by flow cytometery for expression of indicated surface markers. Expression levels of DMSO treated cells are shown in grey outline, treatment with 50nM LBH589 is shown in black outline and unstained auto-florescence is shown in solid grey. Data shown are representative of results from three independent experiments. (B) B16 cells were treated with indicated doses of LBH589 for 48 hours. Cells were washed, then irradiated, loaded with ovalbumin peptide and plated with naöve OTII T-cells for 24 hours. Supernatant was collected and analyzed by ELISA for IFN-γ and IL-2 production. Cytokine levels are compared against DMSO treatment group (**p<0.01, ***p<0.001). (C) B16 and WM793 cells were plated overnight, then treated for 24 hours with indicated doses of LBH589 or DMSO. Expression of mRNA for indicated melanoma antigens was assessed by qRT-PCR. Data shown are representative of results from three independent experiments.